{
  "pmcid": "11728039",
  "sha256": "fb7ffa4e398291d848a00605fec136506bcb17a265bff561e0db3d241cc66607",
  "timestamp_utc": "2025-11-09T23:19:24.750046+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 11.14539260220636,
    "reading_ease": 35.909536015574304,
    "word_count": 268
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial Evaluating PVI for Fluid Responsiveness in Modified Prone Position"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "randomised controlled trial"
      },
      "Participants": {
        "score": 2,
        "evidence": "included 50 patients aged 20-80 years with ASA physical status I-III, excluding those with chronic obstructive pulmonary disease, cardiovascular disease, pulmonary disease, obesity, or renal disorders"
      },
      "Intervention": {
        "score": 2,
        "evidence": "Participants received a 4 mL/kg crystalloid load in both supine and modified prone positions"
      },
      "Objective": {
        "score": 1,
        "evidence": "aimed to evaluate the ability of pleth variability index (PVI) to predict fluid responsiveness in the modified prone position during cervical spine surgery"
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "Fluid responsiveness was defined as a ≥15% increase in stroke volume (SV) measured by FloTrac/Vigileo™"
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Blinding": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "study included 50 patients"
      },
      "Number_Analysed": {
        "score": 2,
        "evidence": "Of 50 patients, 43 were analyzed after excluding those with surgery cancellation or vasoactive drug use"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "The ROC AUCs for ΔPVI, ΔSVV, and ΔPPV were 0.524 (95% CI 0.329–0.730, p = 0.476), 0.749 (95% CI 0.566–0.931, p = 0.004), and 0.790 (95% CI 0.641–0.938, p < 0.001), respectively"
      },
      "Harms": {
        "score": 1,
        "evidence": "No adverse events were reported"
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "The study was registered at ClinicalTrials.gov (NCT04002193)"
      },
      "Funding": {
        "score": 1,
        "evidence": "The study was funded by institutional resources"
      }
    },
    "total_score": 18,
    "max_score": 25
  }
}